Related Experiment Video
Updated: Mar 22, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
Timothy L Chen1, Nikhil Gupta1, Amy Lehman2
1Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, USA.
Abstract:
Epigenetic or transcriptional silencing of important tumor suppressors has been described to contribute to cell survival and tumorigenesis in chronic lymphocytic leukemia (CLL). Using gene expression microarray analysis, we found that thousands of genes are repressed more than 2-fold in CLL compared to normal B cells; however therapeutic approaches to reverse this have been limited in CLL. Following treatment with the Hsp90 inhibitor 17-DMAG, a significant number of these repressed genes were significantly re-expressed. One of the genes significantly repressed in CLL and up-regulated by 17-DMAG was suppressor of cytokine signaling 3, (SOCS3). SOCS3 has been shown to be silenced in solid tumors as well as myeloid leukemia; however little is known about the regulation in CLL. We found that 17-DMAG induces expression of SOCS3 by via the activation of p38 signaling, and subsequently inhibits AKT and STAT3 phosphorylation resulting in downstream effects on cell migration and survival. We therefore suggest that SOCS3 is an important signaling protein in CLL, and Hsp90 inhibitors represent a novel approach to target transcriptional repression in B cell lymphoproliferative disorders which exhibit a substantial degree of gene repression.
Insights
Heat shock protein 90 (Hsp90) inhibitors like 17-DMAG can re-express silenced tumor suppressor genes, such as suppressor of cytokine signaling 3 (SOCS3), in chronic lymphocytic leukemia (CLL). This approach offers a novel strategy for treating B cell lymphoproliferative disorders.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Transcriptional silencing of tumor suppressors contributes to chronic lymphocytic leukemia (CLL) cell survival and tumorigenesis.
- Thousands of genes are repressed in CLL compared to normal B cells, with limited therapeutic options to reverse this silencing.
- Suppressor of cytokine signaling 3 (SOCS3) is known to be silenced in solid tumors and myeloid leukemia, but its regulation in CLL is poorly understood.
Purpose of the Study:
- To investigate the potential of Hsp90 inhibitors to reverse transcriptional repression in CLL.
- To identify specific genes re-expressed by Hsp90 inhibition and elucidate their regulatory mechanisms.
- To evaluate the therapeutic potential of targeting gene repression in B cell lymphoproliferative disorders.
Main Methods:
- Gene expression microarray analysis to compare gene expression profiles in CLL versus normal B cells.
- Treatment of CLL cells with the Hsp90 inhibitor 17-DMAG to assess gene re-expression.
- Analysis of signaling pathways, including p38, AKT, and STAT3 phosphorylation, to understand the mechanism of SOCS3 re-expression.
Main Results:
- Thousands of genes were found to be significantly repressed in CLL compared to normal B cells.
- Treatment with 17-DMAG led to significant re-expression of many repressed genes, including SOCS3.
- 17-DMAG induced SOCS3 expression via p38 signaling activation, inhibiting AKT and STAT3 phosphorylation, which affected cell migration and survival.
Conclusions:
- SOCS3 is an important signaling protein in CLL, and its expression can be restored by Hsp90 inhibition.
- Hsp90 inhibitors represent a novel therapeutic strategy for targeting transcriptional repression in CLL and other B cell lymphoproliferative disorders.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
02:23Abnormal Proliferation